High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease

Bone Marrow Transplantation

Volumn 17, Issue 3, 1996, Pages 383-388

  Lumley, M A ^a   Milligan, D W ^a   Knechtli, C J C ^a   Long, S G ^a   Billingham, L J ^b   McDonald, D F ^c  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c Regional Blood Transfusion Service   (United Kingdom)

Author keywords

Autograft; BEAM; HD; LDH; Peripheral blood progenitor cells

Indexed keywords

CARMUSTINE; CYTARABINE; ETOPOSIDE; LACTATE DEHYDROGENASE; MELPHALAN;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; DEATH; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; MULTIVARIATE ANALYSIS; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RELAPSE; RISK; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW TRANSPLANTATION; CARMUSTINE; COMBINED MODALITY THERAPY; CYTARABINE; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MELPHALAN; MIDDLE AGED; PODOPHYLLOTOXIN; PROGNOSIS; RECURRENCE; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0029918406     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Urba WJ, Longo DL. Hodgkin's disease. New Engl J Med 1992; 326: 678-687.
2. Longo DL, Duffey PL, Young RC et al. Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol 1992; 10: 210-218.
3. Viviani S, Santoro A, Negretti E et al. Salvage chemotherapy in Hodgkin's disease. Ann Oncol 1990; 1: 123-127.
4. Appelbaum FR, Herzig GP, Ziegler JL et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. Blood 1978; 52: 85-92.
5. Philip T, Dumont J, Teillet F et al. High-dose chemotherapy and autologous bone marrow transplantation m refractory Hodgkin's disease. Br J Cancer 1986; 53: 737-742.
6. Carella AM, Congui AM, Gaozza E et al. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian Study Group Report. J Clin Oncol 1988; 6: 1411-1416.
7. Jagannath S, Armitage JO, Dicke KA et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989; 7: 179-185.
8. Philips GL, Wolff SN, Herzig RH et al. Treatment of progressive Hodgkin's disease with intensive chemoradiotherapy and autologous bone marrow transplantation. Blood 1989; 73: 2086-2092.
9. Lasky LC, Hurd DD, Smith JA, Haake R. Peripheral blood stem cell collection and use in Hodgkin's disease: comparison with marrow in autologous transplantation. Transfusion 1989; 29: 323-327.
10. Kessinger A, Bierman PJ. Vose JM, Armitage JO. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991; 77: 2322-2325.
11. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
12. Gribben JG, Linch DC, Singer CRJ et al. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
13. Dreger P, Marquardt P, Haferlach T et al. Effective mobilisation of peripheral blood progenitor cells with Dexa-BEAM and G-CSF: timing of harvesting and composition of the Ieukapheresis product. Br J Cancer 1993; 68: 950-957.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
15. Bierman PJ, Bagin RG, Jagannath S et al. High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: Ions term follow-up in 128 patients. Ann Oncol 1993, 4: 767-773.
16. Chopra R, McMillan AK. Linch DC et al The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease, A single-centre eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
17. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide. carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994; 83: 1193-1199.
18. Fielding AK, Pearce RM, Chopra R et al. Long term outcome in patients with Hodgkin's disease and non-progressive CT abnormalities at six months after BEAM autologous bone marrow transplant. Bone Marrow Transplant 1994; Suppl 1: 150.
19. Strauss DJ, Gaynor JJ, Myers J. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially non-cross resistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990; 7: 1173-1181.
20. Spinolo JA, Jagannath S, Valasquez W et al. Cisplatin-CBV with autologous bone marrow transplantation for relapsed Hodgkin's disease. Leuk Lymphoma 1993; 9: 71-77.
21. Chopra R, Linch DC, McMillan AK et al. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Br J Haematol 1992; 81: 197-202.
22. Gianni AM, Siena S, Bregni M et al. Prolonged disease-free survival after high-dose sequential chemo-radiotherapy and haemopoietic autologous transplantation in poor prognosis Hodgkin's disease. Ann Oncol 1991; 2: 645-653.
23. Hording M, Selby P, Gore M et al. High-dose chemotherapy and autologous bone marrow transplantation for relapsed and refractory Hodgkin's disease. Eur J Cancer 1992; 28A: 1396-1400.
24. Schmitz N, Dreger P, Suttorp M et al. Refractoriness to DexaBEAM salvage chemotherapy predicts refractoriness to high-dose therapy and stem cell rescue in patients with relapsed Hodgkin's disease. Blood 1993; 82: 146a.
25. Stone RM. Myelodysplastic syndrome after autologous transplantation for lymphoma: the price of progress? Blood 1994; 83: 3437-3440.